✦ LIBER ✦

Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs)

✍ Scribed by Andre S Raw; M.Scott Furness; Devinder S Gill; Richard C Adams; Frank O Holcombe Jr.; Lawrence X Yu

Book ID: 113417762
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 973 KB
Volume: 56
Category: Article
ISSN: 0169-409X
DOI: 10.1016/j.addr.2003.10.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Scientific Considerations of Pharmaceuti

Scientific Considerations of Pharmaceutical Solid Polymorphism in Abbreviated New Drug Applications

✍ Lawrence X. Yu; M. Scott Furness; Andre Raw; Kathy P. Woodland Outlaw; Nashed E. 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 94 KB

Scientific Considerations of Pharmaceuti

Scientific Considerations of Pharmaceutical Solid Polymorphism in Regulatory Applications

✍ Stephen P. F. Miller; Andre S. Raw; Lawrence X. Yu 📂 Article 📅 2007 🏛 John Wiley and Sons ⚖ 11 KB

Analysis of regulatory review times of n

Analysis of regulatory review times of new drugs in Japan: association with characteristics of new drug applications, regulatory agency, and pharmaceutical companies

✍ T. Ishibashi; M. Kusama; Y. Sugiyama; S. Ono 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

Common Deficiencies with Bioequivalence

Common Deficiencies with Bioequivalence Submissions in Abbreviated New Drug Applications Assessed by FDA

✍ Qing Liu; Barbara M. Davit; Svetlana A. Cherstniakova; Suman Dandamudi; Johnetta 📂 Article 📅 2011 🏛 American Association of Pharmaceutical Scientists 🌐 English ⚖ 197 KB